111 related articles for article (PubMed ID: 22331798)
21. Epigenetic and genetic analysis of the survivin promoter in acute myeloid leukemia.
Wagner M; Schmelz K; Dörken B; Tamm I
Leuk Res; 2008 Jul; 32(7):1054-60. PubMed ID: 18206228
[TBL] [Abstract][Full Text] [Related]
22. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
[TBL] [Abstract][Full Text] [Related]
23. Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia.
Pabst T; Eyholzer M; Haefliger S; Schardt J; Mueller BU
J Clin Oncol; 2008 Nov; 26(31):5088-93. PubMed ID: 18768433
[TBL] [Abstract][Full Text] [Related]
24. Mutations of NPM1 gene in de novo acute myeloid leukaemia: determination of incidence, distribution pattern and identification of two novel mutations in Indian population.
Ahmad F; Mandava S; Das BR
Hematol Oncol; 2009 Jun; 27(2):90-7. PubMed ID: 19365794
[TBL] [Abstract][Full Text] [Related]
25. Detailed analysis of FLT3 expression levels in acute myeloid leukemia.
Kuchenbauer F; Kern W; Schoch C; Kohlmann A; Hiddemann W; Haferlach T; Schnittger S
Haematologica; 2005 Dec; 90(12):1617-25. PubMed ID: 16330434
[TBL] [Abstract][Full Text] [Related]
26. Fragment length analysis screening for detection of CEBPA mutations in intermediate-risk karyotype acute myeloid leukemia.
Fuster O; Barragán E; Bolufer P; Such E; Valencia A; Ibáñez M; Dolz S; de Juan I; Jiménez A; Gómez MT; Buño I; Martínez J; Cervera J; Montesinos P; Moscardó F; Sanz MÁ
Ann Hematol; 2012 Jan; 91(1):1-7. PubMed ID: 21538063
[TBL] [Abstract][Full Text] [Related]
27. hTERT promoter methylation and telomere length in childhood acute lymphoblastic leukemia: associations with immunophenotype and cytogenetic subgroup.
Borssén M; Cullman I; Norén-Nyström U; Sundström C; Porwit A; Forestier E; Roos G
Exp Hematol; 2011 Dec; 39(12):1144-51. PubMed ID: 21914494
[TBL] [Abstract][Full Text] [Related]
28. Epigenetic changes in therapy-related MDS/AML.
Voso MT; D'Alò F; Greco M; Fabiani E; Criscuolo M; Migliara G; Pagano L; Fianchi L; Guidi F; Hohaus S; Leone G
Chem Biol Interact; 2010 Mar; 184(1-2):46-9. PubMed ID: 19874806
[TBL] [Abstract][Full Text] [Related]
29. FLT3 mutations in a 10 year consecutive series of 177 childhood acute leukemias and their impact on global gene expression patterns.
Andersson A; Paulsson K; Lilljebjörn H; Lassen C; Strömbeck B; Heldrup J; Behrendtz M; Johansson B; Fioretos T
Genes Chromosomes Cancer; 2008 Jan; 47(1):64-70. PubMed ID: 17943971
[TBL] [Abstract][Full Text] [Related]
30. CEBPA methylation as a prognostic biomarker in patients with de novo acute myeloid leukemia.
Lin TC; Hou HA; Chou WC; Ou DL; Yu SL; Tien HF; Lin LI
Leukemia; 2011 Jan; 25(1):32-40. PubMed ID: 20927134
[TBL] [Abstract][Full Text] [Related]
31. Epigenetic inactivation of INK4/CDK/RB cell cycle pathway in acute leukemias.
Chim CS; Wong AS; Kwong YL
Ann Hematol; 2003 Dec; 82(12):738-42. PubMed ID: 14513284
[TBL] [Abstract][Full Text] [Related]
32. Methylation of CTNNA1 promoter: frequent but not an adverse prognostic factor in acute myeloid leukemia.
Chen XX; Lin J; Qian J; Qian W; Yang J; Ma JC; Deng ZQ; An C; Tang CY; Qian Z; Liu Q
Leuk Res; 2014 May; 38(5):613-8. PubMed ID: 24685333
[TBL] [Abstract][Full Text] [Related]
33. AML1/RUNX1 mutations are infrequent, but related to AML-M0, acquired trisomy 21, and leukemic transformation in pediatric hematologic malignancies.
Taketani T; Taki T; Takita J; Tsuchida M; Hanada R; Hongo T; Kaneko T; Manabe A; Ida K; Hayashi Y
Genes Chromosomes Cancer; 2003 Sep; 38(1):1-7. PubMed ID: 12874780
[TBL] [Abstract][Full Text] [Related]
34. Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia.
Scholl S; Theuer C; Scheble V; Kunert C; Heller A; Mügge LO; Fricke HJ; Höffken K; Wedding U
Eur J Haematol; 2008 Mar; 80(3):208-15. PubMed ID: 18081718
[TBL] [Abstract][Full Text] [Related]
35. Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia.
Melki JR; Vincent PC; Clark SJ
Cancer Res; 1999 Aug; 59(15):3730-40. PubMed ID: 10446989
[TBL] [Abstract][Full Text] [Related]
36. Molecular typing of adult acute myeloid leukaemia: significance of translocations, tandem duplications, methylation, and selective gene expression profiling.
Olesen LH; Aggerholm A; Andersen BL; Nyvold CG; Guldberg P; Nørgaard JM; Hokland P
Br J Haematol; 2005 Nov; 131(4):457-67. PubMed ID: 16281935
[TBL] [Abstract][Full Text] [Related]
37. MN1 overexpression is driven by loss of DNMT3B methylation activity in inv(16) pediatric AML.
Larmonie NSD; Arentsen-Peters TCJM; Obulkasim A; Valerio D; Sonneveld E; Danen-van Oorschot AA; de Haas V; Reinhardt D; Zimmermann M; Trka J; Baruchel A; Pieters R; van den Heuvel-Eibrink MM; Zwaan CM; Fornerod M
Oncogene; 2018 Jan; 37(1):107-115. PubMed ID: 28892045
[TBL] [Abstract][Full Text] [Related]
38. AML1/RUNX1 gene point mutations in childhood myeloid malignancies.
Migas A; Savva N; Mishkova O; Aleinikova OV
Pediatr Blood Cancer; 2011 Oct; 57(4):583-7. PubMed ID: 21294243
[TBL] [Abstract][Full Text] [Related]
39. [Flt-3/ITD mutation in pediatric leukemia and its clinical significance].
Wang J; Wang T; Li S; Lin L; Gang Y
Ai Zheng; 2007 Jan; 26(1):58-63. PubMed ID: 17222369
[TBL] [Abstract][Full Text] [Related]
40. miR-10a overexpression is associated with NPM1 mutations and MDM4 downregulation in intermediate-risk acute myeloid leukemia.
Ovcharenko D; Stölzel F; Poitz D; Fierro F; Schaich M; Neubauer A; Kelnar K; Davison T; Müller-Tidow C; Thiede C; Bornhäuser M; Ehninger G; Brown D; Illmer T
Exp Hematol; 2011 Oct; 39(10):1030-1042.e7. PubMed ID: 21784052
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
